Clinical Trial Update: Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating lenalidomide with cyclophosphamide in previously treated hormone-refractory prostate cancer was terminated; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Prostate
• Hormone-refractory Prostate Cancer
• Prostate Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: University of Nebraska | Conditions: Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2018-06-11